Mutual of America Capital Management LLC Acquires New Shares in Vaxcyte, Inc. (NASDAQ:PCVX)

Mutual of America Capital Management LLC acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 48,330 shares of the company’s stock, valued at approximately $3,035,000. Mutual of America Capital Management LLC owned about 0.05% of Vaxcyte at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new stake in shares of Vaxcyte during the first quarter valued at $30,000. Avior Wealth Management LLC purchased a new stake in shares of Vaxcyte during the third quarter valued at $178,000. Wells Fargo & Company MN boosted its position in shares of Vaxcyte by 162.5% during the fourth quarter. Wells Fargo & Company MN now owns 3,961 shares of the company’s stock valued at $190,000 after buying an additional 2,452 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Vaxcyte by 59.9% during the second quarter. Osaic Holdings Inc. now owns 4,073 shares of the company’s stock valued at $200,000 after buying an additional 1,526 shares during the last quarter. Finally, Creative Planning purchased a new stake in shares of Vaxcyte during the fourth quarter valued at $205,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PCVX has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and issued a $95.00 target price on shares of Vaxcyte in a research report on Wednesday, April 10th. Bank of America raised their target price on Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Four research analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte currently has a consensus rating of “Buy” and an average target price of $78.50.

Insider Transactions at Vaxcyte

In other news, SVP Mikhail Eydelman sold 1,667 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $73.87, for a total value of $123,141.29. Following the transaction, the senior vice president now owns 20,710 shares of the company’s stock, valued at $1,529,847.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Mikhail Eydelman sold 1,667 shares of Vaxcyte stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $73.87, for a total transaction of $123,141.29. Following the sale, the senior vice president now owns 20,710 shares of the company’s stock, valued at approximately $1,529,847.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $63.92, for a total value of $958,800.00. Following the sale, the chief executive officer now directly owns 375,814 shares in the company, valued at approximately $24,022,030.88. The disclosure for this sale can be found here. Insiders have sold 101,577 shares of company stock valued at $6,940,475 over the last quarter. 3.60% of the stock is currently owned by company insiders.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX opened at $60.62 on Friday. The stock has a market capitalization of $6.59 billion, a price-to-earnings ratio of -14.68 and a beta of 0.89. The stock’s 50-day simple moving average is $69.67 and its two-hundred day simple moving average is $60.85. Vaxcyte, Inc. has a 52-week low of $41.57 and a 52-week high of $82.04.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same period in the previous year, the company earned ($0.73) earnings per share. As a group, equities analysts forecast that Vaxcyte, Inc. will post -4.18 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.